Triveni生物为针对免疫紊乱的抗体疗法筹集了115M系列B。 Triveni Bio raises $115M Series B for antibody therapies targeting immunological disorders.

来自马萨诸塞州沃特敦的一家生物技术公司Triveni Bio已经筹集了1.15亿美元的B系列资金,以加强针对免疫障碍的抗体疗法。 Triveni Bio, a biotech firm from Watertown, MA, has raised $115 million in Series B funding to enhance its antibody therapies targeting immunological disorders. 这笔资金由 Goldman Sachs Alternatives 牵头，Fidelity 和 Deep Track Capital 出资，将支持开发用于特应性皮炎的 TRIV-509 和用于其他炎症的 TRIV-573。 Led by Goldman Sachs Alternatives, with contributions from Fidelity and Deep Track Capital, the funding will support the development of TRIV-509 for atopic dermatitis and TRIV-573 for other inflammatory conditions. 预计2025年初将提出INDTRIV-509号申请。 An IND application for TRIV-509 is expected in early 2025.